|
| Thursday, March 19, 2020 |
|
|
Eisai: All-case Surveillance Condition for Approval of "Actonel 17.5 mg tablets" for Treatment of Paget's Disease of Bone Cleared in Japan |
| EA Pharma Co., Ltd. and Eisai Co., Ltd. continually strive to promote proper use of the product and provide timely additional information of the product to increase benefits to patients and their families. more info >> |
|
| Tuesday, February 25, 2020 |
|
|
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China |
| Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in China. more info >> |
|
| Friday, February 21, 2020 |
|
|
Eisai Receives the President's Award of the Japan Techno-Economics Society at the 8th Technology Management and Innovation Awards |
| Eisai Co., Ltd. announced today that it received the President's Award at the 8th Technology Management and Innovation Awards held by the Japan Techno-Economics Society (JATES). more info >> |
|
| Wednesday, January 29, 2020 |
|
|
Eisai Commences Joint Research and Development of Cancer Gene Panel Test With Personal Genome Diagnostics Inc. Using Liquid Biopsy to Accelerate Next-Generation Drug Discovery and Development |
| Eisai Co., Ltd. announced today that it has entered into a joint research and development agreement with Personal Genome Diagnostics Inc. for the cancer genetics panel test, and it has initiated the research. more info >> |
|
| Thursday, January 23, 2020 |
|
|
Eisai: Dayvigo (Lemborexant) Approved for Treatment of Insomnia in Japan |
| Eisai Co., Ltd. announced today that it has obtained the manufacturing and marketing approval in Japan for its in-house discovered orexin receptor antagonist DAYVIGO (2.5mg, 5mg, and 10mg tablets, lemborexant) for treatment of insomnia. more info >> |
|
|
Eisai: Approval of Antiepileptic Drug Fycompa in Japan for Monotherapy and Pediatric Indications for Partial-Onset Seizures, as well as a New Formulation |
| The approval for monotherapy for partial-onset seizures is based on the results of a Phase III clinical study (FREEDOM/Study 342) conducted in Japan and South Korea. more info >> |
|
| Monday, January 20, 2020 |
|
|
Eisai Rated "A", the Highest Rating in the CDP Climate Change Report 2019 |
| Eisai Co., Ltd. has announced that it has been selected as the highest-rated company "A" in the Climate Change Report 2019 issued by the CDP, a non-profit organization, as a company that has performed particularly well in response to climate change. more info >> |
|
| Monday, January 6, 2020 |
|
|
Eisai's Fycompa for Adjunctive Treatment of Partial Onset Seizures Launched in China |
| Eisai Co., Ltd. has launched the in-house discovered and developed antiepileptic drug (AED) Fycompa, (generic name perampanel) for use in the adjunctive treatment of partial-onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older. more info >> |
|
| Tuesday, December 24, 2019 |
|
|
Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval |
| Through this collaboration, Gilead Japan will retain responsibility for manufacturing and marketing approval of filgotinib, while Eisai will be responsible for product distribution in Japan in RA and other potential future indications. more info >> |
|
| Monday, December 23, 2019 |
|
|
U.S. FDA Approves Eisai's Dayvigo (Lemborexant) for Treatment of Insomnia in Adult Patients |
| Eisai Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for its in-house discovered and developed orexin receptor antagonist DAYVIGOTM (lemborexant). more info >> |
|
|
|
